Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST)

Historical Holders from Q3 2018 to Q3 2025

Symbol
AQST on Nasdaq
CUSIP
03843E104
Type / Class
Equity / Common Stock, $0.001 par value
Shares outstanding
120M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
66.1M
Holdings value
$369M
% of all portfolios
0.002%
Grand Portfolio weight change
+0%
Number of holders
150
Number of buys
98
Number of sells
-42
Average Value change %
+0%
Average buys %
+0.001%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BRATTON DOUGLAS K 11.1% $23.9M 10.1M BRATTON DOUGLAS K Dec 31, 2024
BlackRock, Inc. 5.3% $35.9M 6.43M BlackRock, Inc. Sep 30, 2025
RTW INVESTMENTS, LP 5.2% $34.9M 6.25M RTW Investments, LP Sep 30, 2025
Venrock Healthcare Capital Partners III, L.P. 2.9% $6.23M 2.63M Venrock Healthcare Capital Partners III, L.P. Dec 31, 2024

Institutional Holders of Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 66.1M $369M +$106M $5.59 150
2025 Q2 47.6M $158M +$12.7M $3.31 115
2025 Q1 44.1M $128M -$2.59M $2.90 120
2024 Q4 43.2M $154M -$13.7M $3.56 112
2024 Q3 46.8M $232M +$19.2M $4.98 116
2024 Q2 42.4M $110M -$9.12M $2.60 94
2024 Q1 41.5M $177M +$87.8M $4.26 96
2023 Q4 29.8K $60.2K +$60.2K $2.02 1
2023 Q3 13.1M $20M +$5.8M $1.53 45
2023 Q2 19.1M $31.4M +$6.9M $1.65 53
2023 Q1 14.9M $17M +$181K $1.14 34
2022 Q4 14.9M $13.5M -$886K $0.90 34
2022 Q3 15.8M $18.5M -$594K $1.17 38
2022 Q2 16.7M $10.6M -$1.2M $0.64 36
2022 Q1 15.5M $40.6M -$1.91M $2.61 48
2021 Q4 16M $62.1M +$1.74M $3.89 49
2021 Q3 14.8M $64.4M -$2M $4.36 44
2021 Q2 15M $59.8M -$7.37M $3.97 54
2021 Q1 15.4M $80.1M -$14.5M $5.20 61
2020 Q4 18.2M $97.6M -$4.07M $5.35 64
2020 Q3 19.9M $96.5M +$6.81M $4.85 57
2020 Q2 18.5M $90M +$16.4M $4.86 55
2020 Q1 16M $35M -$11.2M $2.19 42
2019 Q4 17.4M $101M +$20.6M $5.82 53
2019 Q3 13.3M $42.2M -$3.52M $3.18 30
2019 Q2 14.5M $61M -$1M $4.20 37
2019 Q1 14.4M $99.4M +$1.09M $6.91 44
2018 Q4 14.4M $90.5M -$232M $6.30 35
2018 Q3 16.1M $282M +$282M $17.51 43